Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EBITDA (2022 - 2025)

Historic EBITDA for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$43.9 million.

  • Entrada Therapeutics' EBITDA fell 24492.97% to -$43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.8 million, marking a year-over-year decrease of 28399.12%. This contributed to the annual value of $65.4 million for FY2024, which is 157502.82% up from last year.
  • As of Q3 2025, Entrada Therapeutics' EBITDA stood at -$43.9 million, which was down 24492.97% from -$43.1 million recorded in Q2 2025.
  • Entrada Therapeutics' EBITDA's 5-year high stood at $54.9 million during Q2 2024, with a 5-year trough of -$43.9 million in Q3 2025.
  • Its 4-year average for EBITDA is -$9.3 million, with a median of -$16.9 million in 2025.
  • Per our database at Business Quant, Entrada Therapeutics' EBITDA surged by 53839.13% in 2024 and then plummeted by 24492.97% in 2025.
  • Over the past 4 years, Entrada Therapeutics' EBITDA (Quarter) stood at -$23.9 million in 2022, then soared by 63.02% to -$8.9 million in 2023, then skyrocketed by 101.31% to $116000.0 in 2024, then crashed by 37956.03% to -$43.9 million in 2025.
  • Its last three reported values are -$43.9 million in Q3 2025, -$43.1 million for Q2 2025, and -$16.9 million during Q1 2025.